ProCE Banner Activity

Targeting TROP-2 in Breast Cancer: How Experts Are Integrating TROP-2 ADCs Into Clinical Practice


Download this slideset from a live meeting series for the multidisciplinary team to get up to date on the latest clinical data informing optimal use of TROP-2 antibody–drug conjugates in the treatment of advanced triple-negative breast cancer and HR-positive/HER2-negative metastatic breast cancer, including management of key adverse events associated with these agents.

Released: October 11, 2023



Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.